Get all your news in one place.
100's of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Japan's Fujitsu, Mizuho, PeptiDream to form joint venture to develop COVID-19 treatments

FILE PHOTO: A logo of Fujitsu Ltd. is pictured at the CEATEC JAPAN 2017 (Combined Exhibition of Advanced Technologies) at the Makuhari Messe in Chiba, Japan, October 2, 2017. REUTERS/Toru Hanai

Fujitsu Ltd, Mizuho Financial Group Inc, and drugmaker PeptiDream Inc said on Thursday they are forming a joint venture to develop treatments for COVID-19.

The new company, to be called PeptiAID Inc, will research and develop peptide therapeutics for the current SARS-CoV-2 virus and potential future coronavirus outbreaks, the companies said in a release.

The joint venture also includes Takenaka Corp and Kishida Chemical Co.

FILE PHOTO: Mizuho Financial Group logo is seen at the company's headquarters in Tokyo, Japan August 20, 2018. Picture taken August 20, 2018. REUTERS/Toru Hanai

(Reporting by Rocky Swift; Editing by Kim Coghill)

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.